In a patient with heart failure on sacubitril/valsartan, metoprolol, and hydrochlorothiazide who presents with fatigue, occasional vomiting, and wheezing, is fluid overload likely?

Is Fluid Overload Likely in This Patient?

Yes, fluid overload is likely in this patient with heart failure presenting with fatigue, occasional vomiting, and wheezing, despite being on guideline-directed medical therapy including sacubitril/valsartan.

Clinical Reasoning

The presence of wheezing in a heart failure patient is a red flag for pulmonary congestion, representing fluid accumulation in the lungs. While sacubitril/valsartan has natriuretic and diuretic properties that help reduce congestion 1, breakthrough fluid overload can still occur, particularly if:

• The patient has inadequate loop diuretic dosing (only on hydrochlorothiazide, a thiazide)
• There is medication non-adherence
• Dietary sodium indiscretion has occurred
• Disease progression is present

Key Assessment Points

Look specifically for these congestion markers 2:

• Pulmonary: Wheezing (already present), rales/crackles, orthopnea
• Peripheral: Edema in legs/ankles, weight gain
• Cardiac: Elevated jugular venous pressure (JVP)
• Systemic: Recent weight gain (>2-3 lbs in days)

Critical Medication Gap

This patient is on hydrochlorothiazide rather than a loop diuretic - this is problematic. The 2022 AHA/ACC/HFSA guidelines clearly state that patients with heart failure and significant fluid overload should be treated with intravenous loop diuretics for acute decompensation, and most patients requiring hospitalization will need loop diuretics (not thiazides) at discharge 2.

Hydrochlorothiazide is insufficient for managing volume overload in heart failure patients. Loop diuretics (furosemide, torsemide, bumetanide) are the cornerstone of decongestion therapy 2.

The Sacubitril/Valsartan Context

While sacubitril/valsartan does provide some decongestion benefit through:

• Increased natriuresis (sodium excretion by ~9 mmol/L) 3
• Enhanced diuresis (~39 mL increase) 3
• Reduced NT-proBNP levels 1

It does not replace the need for adequate loop diuretic therapy when congestion is present. The STRONG-HF trial showed that optimal neurohormonal blockade (including sacubitril/valsartan) improved congestion markers but still required appropriate diuretic use 3.

Immediate Action Required

If fluid overload is confirmed on examination:

1. Switch from hydrochlorothiazide to a loop diuretic (furosemide 20-40 mg daily as starting dose, titrate based on response) 2

2. Consider intensifying diuretic therapy if symptoms persist:

   • Increase loop diuretic dose, OR
   • Add a second diuretic (can add back thiazide to loop diuretic) 2

3. Continue sacubitril/valsartan and metoprolol - do not discontinue GDMT during decompensation as this increases mortality risk 2

4. If severe congestion: Patient may require hospitalization for IV loop diuretics 2

Common Pitfall to Avoid

Do not assume sacubitril/valsartan alone will manage volume status - it reduces diuretic requirements compared to ACE inhibitors 3, but patients still need loop diuretics when congested. The "diuretic-centric" approach must be balanced with optimal neurohormonal blockade, not replaced by it 3.